Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod

Abstract

Background Progressive multifocal leukoencephalopathy (PML) caused by JC virus (JCV) is a rare but serious complication of some disease-modifying drugs used to treat multiple sclerosis (MS). Japanese MS patients treated with fingolimod were reported to be 10 times more likely to develop PML than equivalent patients in other countries. The strongest susceptibility human leukocyte antigen ( HLA ) class II alleles for MS are distinct between races ( DRB1*15:01 for Caucasians and DRB1*04:05 and DRB1*15:01 for Japanese); therefore, we investigated whether HLA class II alleles modulate anti-JCV antibody serostatus in Japanese MS patients with and without fingolimod. Methods We enrolled 128 Japanese patients with MS, in whom 64 (50%) were under fingolimod treatment at sampling, and examined the relationship between HLA class II alleles and anti-JCV antibody serostatus. Serum anti-JCV antibody positivity and index were measured using a second-generation two-step assay and HLA-DRB1 and -DPB1 alleles were genotyped. Results HLA-DRB1*15 carriers had a lower frequency of anti-JCV antibody positivity (57% vs 78%, p = 0.015), and lower antibody index (median 0.42 vs 1.97, p = 0.037) than non-carriers. Among patients without HLA-DRB1*15 , DRB1*04 carriers had a higher seropositivity rate than non-carriers (84% vs 54%, p = 0.030), and DPB1*04:02 carriers had a higher anti-JCV antibody index than non-carriers (3.20 vs 1.34, p = 0.008) although anti-JCV antibody-positivity rates did not differ. Patients treated with fingolimod had a higher antibody index than other patients (1.46 vs 0.64, p = 0.039) and treatment period had a positive correlation with antibody index ( p = 0.018). Multivariate logistic regression analysis revealed that age was positively associated, and HLA-DRB1*15 was negatively associated with anti-JCV antibody positivity (odds ratio [OR] = 1.06, p = 0.006, and OR = 0.37, p = 0.028, respectively). Excluding HLA-DRB1*15 -carriers, DRB1*04 was an independent risk factor for the presence of anti-JCV antibody (OR = 5.50, p = 0.023). Conclusions HLA-DRB1*15 is associated with low anti-JCV antibody positive rate and low JCV antibody index, and in the absence of DRB1*15 , DRB1*04 carriers are associ...

A new clustering method identifies multiple sclerosis‐specific T‐cell receptors

“…We revealed that HLA‐DRB1*04:05 increased the CMV‐IgG titer, but did not affect the CMV‐IgG positivity rate, which indicates that HLA‐DRB1*04:05 only influences the humoral immune response to CMV, and not susceptibility to the virus. The humoral immune response to certain viruses, such as JC virus, is well known to change according to the HLA allele 42–44 . CMV itself exerts immunosuppressive effects in hosts to promote virus survival 45,46 .…”

Elevated mycobacterium avium subsp. paratuberculosis (MAP) antibody titer in Japanese multiple sclerosis

“…Previous reports have shown that immune responses of MS patients to certain viruses, such as EBV, cytomegalovirus and JC virus, alter depending on the presence or absence of HLA-DRB1 risk alleles (Olsson et al, 2016;Hayashi et al, 2021;Watanabe et al, 2020). This indicates that HLA alleles may play roles in virus-associated immune responses that are related to MS pathogenesis.…”

Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies

“…For example, studying germline genetics in East Asians may help to explain why PML incidence rates are about 8-fold higher in Japan for fingolimod-treated MS patients compared to the US and worldwide rates ( 66 , 67 ). Presently, a higher rate of JCV seropositivity ( 2 – 5 ) and HLA-DRB1 alleles have been suggested as potential factors for this higher rate of PML development in fingolimod-treated Japanese MS patients ( 68 ).…”